Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Clinical trial NCT03703375 · COMPLETED

Trial details

NCT number: NCT03703375
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Lymphoma, T-Cell

Start date: 2018-11-06
Primary completion: 2021-02-10
Enrollment: 93

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.